Scholarlink

Purpose <p>To investigate metabolic parameters from baseline <sup>18</sup>F-FDG PET/CT as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and disease recurrence in locally advanced breast cancer (LABC) patients.</p> Materials and methods <p>From 142 LABC in 137 patients (bilateral-synchronous BC: 5/137), the following parameters from baseline (pre-treatment) <sup>18</sup>F-FDG PET/CT were retrospectively analyzed, along with clinic-histological data: primary tumor activity (SUVmax, SUVmean, SUVpeak, tumor-to-liver ratio—TLR-, MTV, TLG); lymphoid organs activity (spleen and bone marrow SUVmax and SUVmean, spleen-to-liver ratio—SLR-, bone marrow-to-liver ratio—BLR); and PET-positive lymph-nodes’ number. Predictors of pCR and recurrence-free survival (RFS) were assessed by univariable logistic regression and Cox regression (significant or suggestive association: <i>p</i> &lt; 0.05; <i>p</i> &lt; 0.10).</p> Results <p>74/142 tumors were “Luminal A/B HER2−”, 44/142 “Luminal B HER2+/HER2+”, 24/142 TNBC; pCR after NAC occurred in 26/142 tumors (18.3%) and disease recurrence at follow-up (45 ± 18.1 months) in 25/127 assessable patients (19.7%). Significant or suggestive predictors of NAC response, in Luminal A/B HER2−: lower spleen SUVmax and patients’ age (OR 0.06; 0.93) for pCR; lower TLRmax, TLRmean and BLRmax (OR 1.33; 1.22; and 26.42) for residual disease. Significant negative RFS predictors: higher SUVmax, SUVmean, SUVpeak (HR 1.10; 1.15; 1.11), TLRmax and TLRmean (HR 1.02; 1.00), MTV and TLG (HR 1.32; 1.26) in Luminal A/B HER2−; higher spleen SUVmax, PET-positive nodes’ number&#xa0;and patients’ age (HR 6.24; 1.20; 1.08) in Luminal B HER2+/HER2+.</p> Conclusion <p>Primary tumor and lymphoid organs parameters at baseline <sup>18</sup>F-FDG PET/CT resulted as predictors of NAC response and prognosis in LABC patients, respectively, reflecting the BC cells’ proliferative activity and metabolic burden, and the role of tumor-induced immune-system activation on tumors’ behavior and treatment responsiveness. In LABC candidates to NAC, baseline PET information could improve treatment planning and prognostic stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters

  • 期刊论文

  • 发表日期：

    2025年2月12日

查看全文
  • Silvia Taralli,
  • Armando Orlandi,
  • Pia Clara Pafundi,
  • Valeria Tempesta,
  • Alba Di Leone,
  • Letizia Pontolillo,
  • Lorenzo Scardina,
  • Margherita Lorusso,
  • Ida Paris,
  • Maria Lucia Calcagni

摘要

Purpose

To investigate metabolic parameters from baseline 18F-FDG PET/CT as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and disease recurrence in locally advanced breast cancer (LABC) patients.

Materials and methods

From 142 LABC in 137 patients (bilateral-synchronous BC: 5/137), the following parameters from baseline (pre-treatment) 18F-FDG PET/CT were retrospectively analyzed, along with clinic-histological data: primary tumor activity (SUVmax, SUVmean, SUVpeak, tumor-to-liver ratio—TLR-, MTV, TLG); lymphoid organs activity (spleen and bone marrow SUVmax and SUVmean, spleen-to-liver ratio—SLR-, bone marrow-to-liver ratio—BLR); and PET-positive lymph-nodes’ number. Predictors of pCR and recurrence-free survival (RFS) were assessed by univariable logistic regression and Cox regression (significant or suggestive association: p < 0.05; p < 0.10).

Results

74/142 tumors were “Luminal A/B HER2−”, 44/142 “Luminal B HER2+/HER2+”, 24/142 TNBC; pCR after NAC occurred in 26/142 tumors (18.3%) and disease recurrence at follow-up (45 ± 18.1 months) in 25/127 assessable patients (19.7%). Significant or suggestive predictors of NAC response, in Luminal A/B HER2−: lower spleen SUVmax and patients’ age (OR 0.06; 0.93) for pCR; lower TLRmax, TLRmean and BLRmax (OR 1.33; 1.22; and 26.42) for residual disease. Significant negative RFS predictors: higher SUVmax, SUVmean, SUVpeak (HR 1.10; 1.15; 1.11), TLRmax and TLRmean (HR 1.02; 1.00), MTV and TLG (HR 1.32; 1.26) in Luminal A/B HER2−; higher spleen SUVmax, PET-positive nodes’ number and patients’ age (HR 6.24; 1.20; 1.08) in Luminal B HER2+/HER2+.

Conclusion

Primary tumor and lymphoid organs parameters at baseline 18F-FDG PET/CT resulted as predictors of NAC response and prognosis in LABC patients, respectively, reflecting the BC cells’ proliferative activity and metabolic burden, and the role of tumor-induced immune-system activation on tumors’ behavior and treatment responsiveness. In LABC candidates to NAC, baseline PET information could improve treatment planning and prognostic stratification.